KYNTRA BIO, INC.(KYNB)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,054 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in KYNB
Events flagged as statistical outliers against KYNB's own multi-year baseline — not fixed dollar thresholds.
- Score shock2026-08-13
KYNB quality score dropped 50 points (61→10) on a new filing
View source filing →
KYNB Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for KYNTRA BIO, INC. (KYNB), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores KYNB at 41.6/100 on a 32-signal composite quality model, placing it at rank #2,054 of 2,962 stocks — the bottom half of the AI-ranked universe. KYNB scores in the top quartile across profitability (100.0), balance sheet strength (100.0). Areas of concern include revenue scale (1.2) and free cash flow (2.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 3.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), KYNTRA BIO, INC. reports quarterly revenue of $-1.5M, net income of $12.0M, free cash flow of $-4.0M. Top institutional holders of KYNB by reported 13-F value include ARMISTICE CAPITAL, VANGUARD CAPITAL MANAGEMENT, ACADIAN ASSET MANAGEMENT, based on the most recent SEC filings. KYNB trades on the Nasdaq exchange and files with the SEC under CIK 921299. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KYNB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for KYNTRA BIO, INC. directly from SEC EDGAR. KYNTRA BIO, INC.'s 13F Pro composite quality score has ranged between 10 and 53 since 2026, currently 41.6 — an improving long-term trajectory across 48 quarterly and live scoring snapshots.
Revenue
Q2 2026
$-1.5M
Net Income
Q2 2026
$12.0M
Free Cash Flow
Q2 2026
$-4.0M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-78.3% YoYNet Income
+485.6% YoYOperating Income
+69.5% YoYEPS (Diluted)
+481.6% YoYTotal Assets
-44.3% YoYOp. Cash Flow
+96.5% YoYFree Cash Flow
+96.5% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $6.4M -78.3% | $29.6M -36.7% | $46.8M -66.7% | $140.7M -40.2% | $235.3M +33.5% | $176.3M |
| Net Income | $183.5M +485.6% | $-47.6M +83.3% | $-284.2M +3.2% | $-293.7M -1.3% | $-290.0M -53.2% | $-189.3M |
| Operating Income | $-45.9M +69.5% | $-150.4M +53.4% | $-322.7M -7.2% | $-301.0M -4.3% | $-288.5M -50.4% | $-191.9M |
| EPS (Diluted) | $45.37 +481.6% | $-11.89 -307.2% | $-2.92 +7.0% | $-3.14 +0.0% | $-3.14 -48.8% | $-2.11 |
| Total Assets | $119.6M -44.3% | $214.5M -49.3% | $423.5M -30.6% | $610.1M -21.2% | $773.8M -6.4% | $826.8M |
| Operating Cash Flow | $-4.8M +96.5% | $-138.0M +56.2% | $-315.0M -115.9% | $-145.9M -77.5% | $-82.2M -200.8% | $81.6M |
| Free Cash Flow | $-4.8M +96.5% | $-138.3M +56.5% | $-317.5M -112.2% | $-149.7M -71.2% | $-87.4M -212.6% | $77.6M |
Get alerted when KYNB's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for KYNTRA BIO, INC. including:
Top Institutional Holders of KYNB
ARMISTICE CAPITAL, LLC
$3.0M400,000 shVANGUARD CAPITAL MANAGEMENT LLC
$1.2M159,950 shACADIAN ASSET MANAGEMENT LLC
$795.0K105,585 shSUSQUEHANNA INTERNATIONAL GROUP, LLP
$675.0K89,400 shBlackRock, Inc.
$636.7K84,330 shGEODE CAPITAL MANAGEMENT, LLC
$326.4K43,219 shHighTower Advisors, LLC
$300.1K39,746 shTWO SIGMA INVESTMENTS, LP
$298.3K39,511 shRENAISSANCE TECHNOLOGIES LLC
$204.5K27,081 shVANGUARD FIDUCIARY TRUST CO
$182.0K24,105 sh
| Fund | Value | Shares |
|---|---|---|
| ARMISTICE CAPITAL, LLC | $3.0M | 400,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.2M | 159,950 |
| ACADIAN ASSET MANAGEMENT LLC | $795.0K | 105,585 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $675.0K | 89,400 |
| BlackRock, Inc. | $636.7K | 84,330 |
| GEODE CAPITAL MANAGEMENT, LLC | $326.4K | 43,219 |
| HighTower Advisors, LLC | $300.1K | 39,746 |
| TWO SIGMA INVESTMENTS, LP | $298.3K | 39,511 |
| RENAISSANCE TECHNOLOGIES LLC | $204.5K | 27,081 |
| VANGUARD FIDUCIARY TRUST CO | $182.0K | 24,105 |
Companies Similar to KYNB
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Strata Critical Medical, Inc.
MeiraGTx Holdings plc
AGENUS INC
SANUWAVE Health, Inc.
BIOLIFE SOLUTIONS INC
Apellis Pharmaceuticals, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put KYNB on your watchlist
Track score changes the day KYNTRA BIO, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is KYNB a good stock to buy?
13F Pro's AI-powered analysis of KYNTRA BIO, INC. (KYNB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for KYNB are available on the KYNB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. KYNB is classified as a small company.
Which hedge funds own KYNB?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling KYNB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of KYNTRA BIO, INC.'s investment landscape.